1. Home
  2. EU vs IMMP Comparison

EU vs IMMP Comparison

Compare EU & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo enCore Energy Corp.

EU

enCore Energy Corp.

HOLD

Current Price

$2.79

Market Cap

464.5M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.78

Market Cap

426.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EU
IMMP
Founded
2009
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.5M
426.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EU
IMMP
Price
$2.79
$2.78
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
3.7M
187.7K
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,142,000.00
$3,306,742.00
Revenue This Year
$17.41
$292.48
Revenue Next Year
$95.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.28
52 Week Low
$1.01
$1.32
52 Week High
$4.19
$3.53

Technical Indicators

Market Signals
Indicator
EU
IMMP
Relative Strength Index (RSI) 44.88 47.85
Support Level $2.60 $2.56
Resistance Level $3.13 $3.23
Average True Range (ATR) 0.26 0.14
MACD -0.08 -0.05
Stochastic Oscillator 16.67 31.34

Price Performance

Historical Comparison
EU
IMMP

About EU enCore Energy Corp.

enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: